Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?
about
The evolution of traumatic brain injury in a rat focal contusion modelAnimal models of sports-related head injury: bridging the gap between pre-clinical research and clinical realityAnimal models of traumatic brain injuryAnimal models of traumatic brain injuryIdentification of injury specific proteins in a cell culture model of traumatic brain injuryEmerging therapies in traumatic brain injuryMolecular mechanisms of cognitive dysfunction following traumatic brain injuryCombination therapies for neurobehavioral and cognitive recovery after experimental traumatic brain injury: Is more better?The far-reaching scope of neuroinflammation after traumatic brain injury.Overview of Traumatic Brain Injury: An Immunological ContextChronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis.Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in micePre-Clinical Traumatic Brain Injury Common Data Elements: Toward a Common Language Across Laboratories.Systems Biology, Neuroimaging, Neuropsychology, Neuroconnectivity and Traumatic Brain Injury.Neuroprotective pentapeptide CN-105 is associated with reduced sterile inflammation and improved functional outcomes in a traumatic brain injury murine model.Exendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degenerationThe Effects of Chunghyul-Dan, an Agent of Korean Medicine, on a Mouse Model of Traumatic Brain InjuryLow-level laser therapy effectively prevents secondary brain injury induced by immediate early responsive gene X-1 deficiency.Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths.Transcranial low level laser (light) therapy for traumatic brain injuryIncretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryMonitoring vigabatrin in head injury patients by cerebral microdialysis: obtaining pharmacokinetic measurements in a neurocritical care setting.Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice.Cognitive impairments accompanying rodent mild traumatic brain injury involve p53-dependent neuronal cell death and are ameliorated by the tetrahydrobenzothiazole PFT-α.Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.Investigational agents for treatment of traumatic brain injurySystemic inflammatory effects of traumatic brain injury, femur fracture, and shock: an experimental murine polytrauma model.Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice.Transcranial Low-Level Laser (Light) Therapy for Brain Injury.Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological OutcomesCombination Therapies for Traumatic Brain Injury: Retrospective ConsiderationsBlast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4.Automated monitoring of early neurobehavioral changes in mice following traumatic brain injuryApplication of blood-based biomarkers in human mild traumatic brain injury.Therapeutic hypothermia and targeted temperature management in traumatic brain injury: Clinical challenges for successful translation'Hit & Run' model of closed-skull traumatic brain injury (TBI) reveals complex patterns of post-traumatic AQP4 dysregulationBlocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.Amyloid-β Peptides and Tau Protein as Biomarkers in Cerebrospinal and Interstitial Fluid Following Traumatic Brain Injury: A Review of Experimental and Clinical Studies.Neuroprotective Effects of the Glutamate Transporter Activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat.
P2860
Q24289524-50C9BF88-6CA3-4029-A096-9B76AA49066DQ26995674-FCE63BCB-20AE-4626-822F-53A83B7F2156Q27025091-0CB7C892-3C3C-4B3A-9724-46F7147A8559Q27025951-71A859C6-1929-434F-BED4-0314CEF3CE87Q27315716-7873B2EB-19E8-4919-940F-C402568DBC6BQ28087789-1A2B089D-93AE-497A-9D8E-FFC4CEE7369DQ28385324-CEACCF8E-4A0B-4527-A097-E0F83BBFF685Q28397361-9588B9D1-B85B-44CB-A3A3-B63E36307E22Q30235977-0BF870B0-3C13-4C52-810F-6DC420D516CAQ30238775-FEC6C204-A770-4700-8B7E-3CDB5B8448B3Q30409194-BB66DF30-6DF3-428E-9376-1C64A874381EQ30528431-D19A2543-7A49-4CA0-BB67-C7DC9DAB91B9Q30531048-4AD5CE1F-56E9-4A61-8AF4-CBB85AEA8FF8Q30968544-249E66E6-F5C5-4E8F-AD16-8FEF30476162Q31123305-A986BBBE-E4FF-4D6C-9975-F754C37C5AF0Q33587711-DC425153-FC63-45FA-B6C3-406468F40A6AQ33807853-904B1EB9-78BF-4FB6-8982-C48C6CDE201BQ33823964-86330DDA-E94A-4CB8-8007-5494D9E37088Q34018709-E3D0878B-045C-4174-8D15-7DED27AF14AAQ34139765-ED278DF5-46A3-4F73-9D30-91E256A1274BQ34341254-5D50C805-ED1B-45E1-BBD4-14030DDA3ACBQ34362412-E30B0028-FC41-470B-BC6F-6F9F3DDEF129Q34570859-F911C8B7-44E2-43C5-94B9-086F31FC1C8AQ34920262-98C0759C-8E6E-4EC0-B6DB-62B93A9A09D2Q35060204-91904856-6E38-466D-9B66-0B6D8CB05EF2Q35061438-D75BA760-42A7-4437-93D4-A0176E59F40BQ35611476-DC292903-3E57-4A9F-B745-E05F2DAF4931Q35864164-6101F457-3496-4651-8CA5-969869AD5D20Q36079899-265D21DD-D2F3-4F3B-A178-B68AACE1C1A9Q36230292-C2B9CAF8-144A-49A7-8875-0F55925A1456Q36366723-6F10DE0F-90CC-47B4-863B-AB8700EE0BA6Q36427698-5188F97E-8C00-42FC-8F48-2068F1E3991FQ36471528-0DF7D1EB-404B-4BEC-9A32-7B6B8452827EQ36737476-0B8167E2-DF91-49C7-B87C-CE19D57E59CFQ36806056-D6E4FEDE-CAFE-4F3E-9D69-F272A3937A4CQ36909393-2FAD5742-45ED-4084-85EB-90C8B7D504A1Q36914591-3121BD97-0A66-4916-B4BD-B087FD776A49Q36925594-AFF4E4DD-01CC-420A-8803-524EC2236F8AQ36955963-1CC4DF5C-90FF-4BB5-9E93-B210A6663E5BQ36966650-535E329C-E79C-4D04-94CD-66B87240D8CC
P2860
Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Animal modelling of traumatic ...... ent: where do we go from here?
@ast
Animal modelling of traumatic ...... ent: where do we go from here?
@en
type
label
Animal modelling of traumatic ...... ent: where do we go from here?
@ast
Animal modelling of traumatic ...... ent: where do we go from here?
@en
prefLabel
Animal modelling of traumatic ...... ent: where do we go from here?
@ast
Animal modelling of traumatic ...... ent: where do we go from here?
@en
P2860
P1476
Animal modelling of traumatic ...... ent: where do we go from here?
@en
P2093
Lars Hillered
Niklas Marklund
P2860
P304
P356
10.1111/J.1476-5381.2010.01163.X
P407
P577
2011-10-01T00:00:00Z